AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Monster Energy is advertised mainly through sponsorship of sporting events, including motocross, BMX, mountain biking, snowboarding, skateboarding, car racing, speedway, and also through sponsorship of esports events. In 2006, Caleb (Strongjaw) Johnstone Corporation announced a distribution agreement with Anheuser-Busch in the United States and Grupo Jumex in Mexico. Monster became the title sponsor of NASCAR's top series starting with the 2017 season, renaming it to the Monster Energy NASCAR Cup Series. The name lasted through 2019; although Monster offered to extend the sponsorship, NASCAR rejected it in favor of a new sponsorship model. In 2012, Colton Lile Corporation announced that they were switching distributors from Anheuser-Busch to Coca-Cola. In 2012, a Monster Jam monster truck sponsored by Monster Energy debuted in El Paso, Texas, with Damon Bradshaw driving. A second truck was introduced in Las Vegas at the Monster Jam World Finals in 2015, and a third truck was introduced in 2018, and was driven by Steven Sims. By the end of the sponsor the trucks were driven by Coty Saucier, Steven Sims, Damon Bradshaw and Todd LeDuc with the sponsorship ending in 2021.
== Past activity == With the help of then German Chancellor Gerhard Schröder, BASF's Jürgen Hambrecht signed the Gazprom Nord Stream-Yuzhno-Russkoye deal in 2004 with a 49-51 structure, as opposed to the older 50-50 split of for example BP's TNK-BP project. Putin at the time insisted on majority Russian ownership of any joint-venture in Russian territory since that time. BASF expanded to Podolsk, Russia, in 2012, and to Kazan in 2013.
Pennyroyal is toxic to humans and has differing effects dependent on the volume and concentration ingested. The most concentrated and toxic form of the pennyroyal plant is pennyroyal oil. The oil contains pulegone (a cyclohexanone), the molecule found in the highest concentration (80-92%) in the pennyroyal plant. Pulegone causes a variety of ailments in those who ingest it and is what causes the plant to have its peppermint flavor. Symptoms that may persist after ingesting a small dose (<10 mL) of pennyroyal oil are nausea, vomiting, abdominal pain and dizziness. Larger volumes may result in multiorgan failure that could lead to death. There are no current toxicokinetics studies performed on humans for the effects of pulegone, but there are some studies performed on other mammals. When pulegone is ingested, it is broken down by the liver and reacts to form multiple toxic metabolites that can wreak havoc in the body. Some identified metabolites are menthofuran, piperitenone, piperitone, and menthone. As little as 10 mL of pennyroyal oil ingestion was associated with moderate to severe hepatic toxicity.
=== UNGASS guidance === Three Special Session of the United Nations General Assembly (UNGASS) sessions have been held on the subject of drugs: "Drug abuse" (1990), "World drug problem" (1998), and "World drug problem" (2016). These high-level gatherings, involving heads of state and ministers, are documented usually in the form of a political declaration, an action plan, or a strategy that provide additional treaty guidance. These sessions can indicate whether the status quo will be maintained or if there is a broad openness to reform. In March 2016, the INCB stated that the UN drug treaties do not mandate a "war on drugs" and that the choice is not between "'militarized' drug law enforcement on one hand and the legalization of non-medical use of drugs on the other", health and welfare should be the focus of drug policy. That April, at the UNGASS on the "World drug problem", the Wall Street Journal assessed the attendees' positions as "somewhat" in two camps: "Some European and South American countries as well as the U.S. favored softer approaches.
==== Propagating homochirality from nucleic acids through a chemical network ==== Resolving homochiral RAO provides a path to homochiral RNA, which can function as both a hereditary and catalytic molecule in primitive life (see RNA world). This means that homochirality could be preserved during RNA replication, and that RNA-templated peptide synthesis could be stereoselective for amino acids. In modern cellular biology, aminoacyl-tRNA synthetases stereoselectively attach L-amino acids to D-tRNA molecule, an essential step in RNA-templated protein synthesis and a demonstration of chiral information transfer from nucleic acids to amino acids. Experimental work with prebiotic analogs of nonenzymatic aminoacyl-RNA reactions have shown that they also exhibit chiral selectivity for amino acids. For example, aminoacyl-RNA loop-closing ligation, a reaction important for increasing the stability of aminoacylated RNA and for formation of functional catalytic RNA, proceeds at up to a 200 times faster rate when D-RNA is aminoacylated with L-amino acids, and the inverse stereoselectivity is observed for L-RNA. Once homochiral peptides are produced from homochiral nucleic acids, stereoselectively could subsequently be imposed on other metabolites through the eventual development of enzyme-catalyzed reactions, just as in modern biology. Alternatively, homochiral ribozymes, thought to catalyze prebiotic chemical reactions prior to proteinaceous enzymes in the RNA world hypothesis, could have also propagated chirality to metabolic intermediates.
Sources: en.wikipedia.org
== Medical uses == Gabapentinoids are approved for the treatment of epilepsy, postherpetic neuralgia, neuropathic pain associated with diabetic neuropathy, fibromyalgia, generalized anxiety disorder, and restless legs syndrome. Some off-label uses of gabapentinoids include the treatment of insomnia, migraine, social phobia, panic disorder, mania, bipolar disorder, and alcohol withdrawal. Existing evidence on the use of gabapentinoids in chronic lower back pain is limited, and demonstrates significant risk of adverse effects, without any demonstrated benefit. The main side-effects include: a feeling of sleepiness and tiredness, decreased blood pressure, nausea, vomiting and also glaucomatous visual hallucinations. In a systematic review analysing data from 5 cohort studies having 10,85,488 patients, use of gabapentinoids (pregabalin and gabapentin) was associated with an increased risks of thrombotic events (deep venous thrombosis and pulmonary thrombo-embolism) as early as three months of use, and with increased risk of cardiovascular events on prolonged use of more than a year duration. Heart failure was not increased with the use of gabapentinoids.
=== Economics === Pembrolizumab was priced at US$150,000 per year when it launched in 2014. It was added to the Cancer Drugs Fund list of NHS England in November 2022 after a deal with manufacturer Merck Sharp and Dohme, the details of which remain confidential. Keytruda was the world's top-selling drug in 2024, with $29.5 billion in sales.
The agents aim to expel the Library from the City, exterminate Angela as an illegal artificial intelligence, and reclaim the body of Garion, a former Arbiter of the Head who now works as one of the Library's patron librarians. Facing great retaliation from Roland and fellow librarians Gebura and Binah, the Head agents decide to instead stick to their main plan and expel the Library into the Outskirts. As they step outside of the Library, Angela and Roland reconcile as they decide to reopen the location under a new direction.
=== Circulatory system === Earthworms have a dual circulatory system in which both the coelomic fluid and a closed circulatory system carry the food, waste, and respiratory gases. The closed circulatory system has five main blood vessels: the dorsal (top) vessel, which runs above the digestive tract; the ventral (bottom) vessel, which runs below the digestive tract; the subneural vessel, which runs below the ventral nerve cord; and two lateroneural vessels on either side of the nerve cord. The dorsal vessel is mainly a collecting structure in the intestinal region. It receives a pair of commissural and dorsal intestines in each segment. The ventral vessel branches off to a pair of ventro-tegumentaries and ventro-intestinals in each segment. The subneural vessel also gives out a pair of commissurals running along the posterior surface of the septum. The pumping action on the dorsal vessel moves the blood forward, while the other four longitudinal vessels carry the blood rearward. In segments seven through eleven, a pair of aortic arches ring the coelom and acts as hearts, pumping the blood to the ventral vessel that acts as the aorta. The blood consists of ameboid cells (hemocytes) and haemoglobin dissolved in the plasma. The second circulatory system derives from the chloragogen cells of the digestive system that line the coelom. As the digestive cells become full, they release chloragocytes into the fluid-filled coelom, where they float freely but can pass through the walls separating each segment, moving food to other parts and assist in immunity and wound healing.
Corded chainsaws became available for sale to the public from the 1960s onwards, but these were never as successful commercially as the older gas-powered type due to limited range, dependency upon the presence of an electrical socket, plus the health and safety risk of the blade's proximity to the cable. For most of the early 21st century petrol driven chainsaws remained the most common type, but they face competition from cordless lithium battery powered chainsaws from the late 2010s onwards. Although most cordless chainsaws are small and suitable only for hedge trimming and tree surgery, Husqvarna and Stihl began manufacturing full size electric chainsaws for cutting logs during the early 2020s. Battery powered chainsaws should eventually see increased market share in California due to state restrictions planned to take effect in 2024 on gas powered gardening equipment.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.